Psychedelic Medicine Catalyst Seminar Stock Image

Catalyst Presents: Canadian Psychedelic Medicine Seminar

Coinciding with Mental Health Week in Canada, Catalyst Presents — an Alberta-based non-profit company — organized a two-day seminar dedicated to psychedelic medicine from May 7-9.

As psychedelic medicines appear to be on the cusp of reforming mental healthcare and therapy with breakthrough developments, the seminar brought together over 70 presenters discussing multiple branches of psychedelics, including current hot topics such a the Multidisciplinary Association for Psychedelic Studies’ (MAPS) Phase III trial results for MDMA-assisted therapy, and ketamine-assisted therapy.

The Catalyst Summit was first inaugurated in May 2020. A brainchild of David Harder, the founder of ATMA Journey Centers, the event was founded to promote an exchange of discourse on the scientific, cultural, and legal developments of psychedelic medicines. 

The event kicked off on Friday evening with a discussion on psilocybin, moderated by Harder and Natalie Harder, Program Director with ATMA Journey Centers, and was followed by a presentation on MAPS’ Phase III MDMA clinical trial.

Canada has emerged as a leader in the ongoing psychedelic renaissance. With Health Canada breaking the ice last year by permitting limited legal access, the country has now allowed at least 30 patients to undergo psychedelic-assisted therapy, while also exempting the legal administration of psilocybin to select healthcare professionals for training purposes.

Bruce Tobin, founder of TheraPsil — a non-profit organization that carried out the first four psychedelic-assisted therapies in August 2020 — spoke about his experience treating patients via a legal exemption for psilocybin. Thomas Hartle, the first Canadian to undergo the therapy, was also present and shared details of his life-changing experience.

See Also
Explaining Psychedelics Image

Canadian advocates and researchers including Gillian Maxwell, Trevor Millar, and Erika Dyck touched upon issues surrounding the legalization and decriminalization of psychedelics in Canada. The medical assistance in dying (MAID) campaign to include psychedelic therapy was the most recent initiative brought up during the seminar.

Catalyst Presents partnered with MindCure, ATMA Journey Centers, and the Canadian Psychedelic Association to produce the event. 

An in-person event for next year has already been scheduled for May 27-May 29, 2022, in Calgary, Alberta.

What makes peyote unique among psychedelics?

Lophos Pharma is a #peyote focused psychedelics company co-founded by wife and husband duo Claire and Evan Stawnyczy to explore mescaline’s therapeutic potential.

Read the full interview here: http://ow.ly/kN6w50I3vzt

The push for medical #DMT is on. Truffle Report looks at top corporate and scientific developments involving the spirit molecule from @mindmedco, @AlgernonPharma, @entheonbiomed, @SmallPharma and more.

Full article here: http://ow.ly/khee50HXOHz

#science #business #medicine

Our CEO and Co-Founder @flobrand spoke to @amanda_siebert @Forbes to give deeper context on the significance of our donation to @MAPS and the importance of collaboration between for-profit and non-profits in tackling the #mentalhealth crisis.

See: https://www.forbes.com/sites/amandasiebert/2022/02/16/exclusive-maps-accepts-500k-donation-from-atai-life-sciences-philanthropy-arm/

A Hawaii legislative committee has approved a bill that proposes the establishment of a working group to study the therapeutic benefits of #psilocybin by a vote of 5-0.

Read the full story here: http://ow.ly/4WWI50HWJtL

#psychedelics #healing #medicine #hawaii #legal

"Inspired by a device created by in the 1950s, the creators hope to bring free transcendental experiences to 100,000 Britons – and unite the country through communal hallucinations"

https://www.theguardian.com/artanddesign/2022/feb/16/dreamachine-unboxed-brion-gysin-jon-hopkins-assemble

Load More...

Related Articles

Scroll To Top